DexCom, Inc. (DXCM) Net Profit Margin: 19.31%
Is DexCom, Inc.’s net profit margin high or low?
DexCom, Inc.'s net profit margin of 19.31% is 24% above its 5-year average of 15.57%, around the middle of its 5-year range (8.86%–25.62%).
The net profit margin for DexCom, Inc. (DXCM) is 19.31% as of Wednesday, June 10, 2026. It is above its 12-month average by 19.83% (16.12%).
DXCM Net Profit Margin Chart
DXCM Average Net Profit Margin Chart
DXCM Current vs Average Net Profit Margin Chart
DXCM Net Profit Margin Metrics
NET PROFIT MARGIN
19.31%
NET PROFIT MARGIN AVG TTM
16.12%
NET PROFIT MARGIN AVG 3Y
14.73%
NET PROFIT MARGIN AVG 5Y
15.57%
NET PROFIT MARGIN AVG 10Y
5.01%
NET PROFIT MARGIN AVG 15Y
-12.42%
NET PROFIT MARGIN AVG 20Y
-194.24%
CURRENT VS TTM AVG
+19.83%
CURRENT VS 3Y AVG
+31.12%
CURRENT VS 5Y AVG
+24.06%
CURRENT VS 10Y AVG
+285.08%
CURRENT VS 15Y AVG
+255.44%
CURRENT VS 20Y AVG
+109.94%
DXCM Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | — | 19.31% | 16.12% | 14.73% | 15.57% |
| Biogen Inc. (BIIB) | $29.00B | 13.92% | 15.03% | 17.95% | 19.29% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.33% | 8.63% | 8.47% | 7.22% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.44% | 27.22% | 24.83% | 24.72% |
| Centene Corporation (CNC) | $31.94B | -3.25% | -0.70% | 0.29% | 0.65% |
| Zoetis Inc. (ZTS) | $34.20B | 27.79% | 27.55% | 27.17% | 26.57% |
| Waters Corporation (WAT) | $23.83B | 11.91% | 20.93% | 21.85% | 22.39% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.40% | 21.94% | 21.74% | 21.20% |
| BioNTech SE (BNTX) | $21.81B | -44.73% | -31.89% | 3.77% | 12.08% |
| Agilent Technologies, Inc. (A) | $37.17B | 19.55% | 19.27% | 18.75% | 17.94% |
Margin Comparison
Operating Margin
21.4%
Net Profit Margin
19.3%
DexCom, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Net Profit Margin FAQ
- What is the net profit margin for DexCom, Inc. (DXCM)?
- The net profit margin for DXCM stock is 19.31%.
- Is DexCom, Inc.'s net profit margin high or low?
- DexCom, Inc.'s net profit margin of 19.31% is 24% above its 5-year average of 15.57%, around the middle of its 5-year range (8.86%–25.62%).
- What is the TTM average net profit margin for DexCom, Inc. (DXCM)?
- The TTM average net profit margin for DXCM stock is 16.12%.
- What is the 3Y average net profit margin for DexCom, Inc. (DXCM)?
- The 3Y average net profit margin for DXCM stock is 14.73%.
- What is the 5Y average net profit margin for DexCom, Inc. (DXCM)?
- The 5Y average net profit margin for DXCM stock is 15.57%.
- What is the 10Y average net profit margin for DexCom, Inc. (DXCM)?
- The 10Y average net profit margin for DXCM stock is 5.01%.
- What is the 15Y average net profit margin for DexCom, Inc. (DXCM)?
- The 15Y average net profit margin for DXCM stock is -12.42%.
- What is the 20Y average net profit margin for DexCom, Inc. (DXCM)?
- The 20Y average net profit margin for DXCM stock is -194.24%.
DexCom, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 17.94% |
| 2024-12-31 | 14.29% |
| 2023-12-31 | 14.95% |
| 2022-12-31 | 11.73% |
| 2021-12-31 | 8.86% |
| 2020-12-31 | 25.62% |
| 2019-12-31 | 6.85% |
| 2018-12-31 | -12.32% |
| 2017-12-31 | -6.99% |
| 2016-12-31 | -11.44% |
| 2015-12-31 | -14.33% |
| 2014-12-31 | -8.64% |
| 2013-12-31 | -18.62% |
| 2012-12-31 | -54.55% |
| 2011-12-31 | -58.67% |
| 2010-12-31 | -113.45% |
| 2009-12-31 | -180.26% |
| 2008-12-31 | -560.93% |
| 2007-12-31 | -991.53% |
| 2006-12-31 | -2147.64% |
| 2005-12-31 | 0.00% |
| 2004-12-31 | 0.00% |
| 2003-12-31 | 0.00% |
| 2002-12-31 | 0.00% |
| 2001-12-31 | 0.00% |
| 2000-12-31 | 0.00% |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach